Lifesci Capital Expects Increased Earnings for CG Oncology

CG Oncology, Inc. (NASDAQ:CGON) – Research analysts at Lifesci Capital lifted their FY2026 earnings per share estimates for shares of CG Oncology in a report issued on Monday, March 2nd. Lifesci Capital analyst S. Slutsky now forecasts that the company will earn ($2.90) per share for the year, up from their previous estimate of ($3.18). The consensus estimate for CG Oncology’s current full-year earnings is ($1.31) per share.

CG Oncology (NASDAQ:CGON) last announced its earnings results on Friday, February 27th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.10. The business had revenue of $2.32 million for the quarter.

Several other brokerages have also commented on CGON. Royal Bank Of Canada increased their price objective on shares of CG Oncology from $61.00 to $73.00 and gave the company an “outperform” rating in a research report on Wednesday, January 21st. The Goldman Sachs Group restated a “buy” rating and set a $82.00 price target on shares of CG Oncology in a research note on Monday, January 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CG Oncology in a report on Wednesday, January 21st. Truist Financial boosted their price objective on shares of CG Oncology from $66.00 to $75.00 and gave the company a “buy” rating in a report on Tuesday, February 10th. Finally, Morgan Stanley set a $93.00 target price on CG Oncology in a research report on Friday, January 9th. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $69.00.

CG Oncology Stock Performance

Shares of NASDAQ CGON opened at $61.57 on Wednesday. The company has a market cap of $5.20 billion, a PE ratio of -29.74 and a beta of 1.18. The business has a 50-day simple moving average of $51.60 and a two-hundred day simple moving average of $42.92. CG Oncology has a fifty-two week low of $14.80 and a fifty-two week high of $63.58.

Institutional Investors Weigh In On CG Oncology

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Whittier Trust Co. of Nevada Inc. purchased a new position in shares of CG Oncology in the fourth quarter valued at approximately $27,000. Strengthening Families & Communities LLC purchased a new position in CG Oncology in the 3rd quarter valued at approximately $40,000. Comerica Bank grew its stake in shares of CG Oncology by 100.4% in the fourth quarter. Comerica Bank now owns 1,028 shares of the company’s stock worth $43,000 after acquiring an additional 515 shares in the last quarter. Winthrop Capital Management LLC purchased a new stake in shares of CG Oncology during the second quarter worth $38,000. Finally, Picton Mahoney Asset Management acquired a new stake in shares of CG Oncology in the fourth quarter valued at $118,000. Institutional investors and hedge funds own 26.56% of the company’s stock.

Insider Activity at CG Oncology

In related news, Director James Mulay sold 11,145 shares of the firm’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $52.47, for a total transaction of $584,778.15. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 7.40% of the stock is owned by insiders.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.